Inactive Instrument

Analyst Reco. IVERIC bio, Inc.

Equities

ISEE

US46583P1021

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

TD Cowen Downgrades IVERIC bio to Market Perform From Outperform	23-05-08	MT
B. Riley Raises IVERIC bio's Price Target to $40 From $19 on Heels of Announced Sale to Astellas, Keeps Neutral Rating	23-05-05	MT
Baird Downgrades IVERIC bio to Neutral From Outperform, Price Target is $40	23-05-04	MT
UBS Downgrades IVERIC bio to Neutral From Buy, Adjusts Price Target to $40 From $34	23-05-03	MT
HC Wainwright Downgrades IVERIC bio to Neutral From Buy, Adjusts Price Target to $40 From $35	23-05-02	MT
ANALYST RECOMMENDATIONS : Comcast, Ferrari, Hershey, Microsoft, Mondelez...	23-05-02
Wedbush Downgrades IVERIC bio to Neutral From Outperform After News of Planned Sale to Astellas Pharma, Raises PT to $40 From $35	23-05-01	MT
Guggenheim Downgrades IVERIC bio to Neutral From Buy, Cuts Price Target to $40 From $43	23-05-01	MT
Morgan Stanley Adjusts Price Target on IVERIC bio to $35 From $30, Maintains Overweight Rating	23-04-25	MT
Wedbush Raises IVERIC bio's PT to $35 From $29, Updates Model to Include Increased Market Share for Avacincaptad Pegol; Keeps Outperform Rating	23-04-24	MT
Credit Suisse Raises IVERIC bio's Price Target to $34 From $32, Says Continues to Offer Compelling Relative Value, Maintains Outperform Rating	23-02-21	MT
B. Riley Raises IVERIC bio's Price Target to $19 From $17, Keeps Neutral Rating	23-02-21	MT
Jefferies Downgrades IVERIC bio to Hold From Buy, Adjusts Price Target to $20 From $30	22-11-10	MT
B. Riley Lowers IVERIC bio's Price Target to $17 From $19, Keeps Neutral Rating	22-11-07	MT
Credit Suisse Raises IVERIC bio's Price Target to $32 From $27, Keeps Outperform Rating	22-11-04	MT
HC Wainwright Adjusts Price Target on IVERIC bio to $35 From $26, Maintains Buy Rating	22-11-04	MT
UBS Raises IVERIC bio Price Target to $26 From $20, Maintains Buy Rating	22-10-18	MT
B. Riley Securities Upgrades IVERIC bio to Neutral from Sell, Raises Price Target to $19 from $8 Reflecting Estimated Market Share Gain from Competitors	22-10-18	MT
Wedbush Raises Price Target for IVERIC bio to $29 From $22, Maintains Outperform Rating	22-10-17	MT
Stifel Nicolaus Raises IVERIC bio's Price Target to $35 From $28, Keeps Buy Rating	22-09-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IVERIC bio, Inc.

Equities

ISEE

US46583P1021

Analyst Reco.

Filters